LICENSING AGREEMENTS (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	Dec. 28, 2020	May 17, 2017	Mar. 31, 2022	Mar. 31, 2021	Jan. 08, 2021	Sep. 30, 2020	Dec. 12, 2019	Feb. 02, 2016
Company Paid Cmh				$ 50,000	$ 50,000	$ 40,000
Common Stock Issue				89,286	133	84,656	6,667
Obligation Of The Initial Payment				$ 300,000	$ 300,000	$ 300,000
License Fees	$ 250,000
Cash Payment In Intial Payment							$ 50,000
License Agreement Description	the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
Continuing Royalty Description			Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™
No Of Share Exchange								431,111
Restricted Common Stock								$ 100,000
Amortization Expenses			$ 23,021	23,021
Stemspine LLC [Member]
Royalty Payment Percentage		5.00%
Non-royalty Sublease Income Percentage.		50.00%
Patents [Member]
Amortization Expenses			2,493	2,493
Carrying Value Of Patent			$ 38,494
Expiration Period Of Finite-lived Intangible Assets			2026
Expected Amount Of Amortization			$ 9,972
Patents [Member] | Creative Medical Health Inc [Member]
Amortization Expenses			293	293
Carrying Value Of Patent			$ 190,829
Expiration Period Of Finite-lived Intangible Assets			2027
Initial Payment		$ 100,000
Expected Amount Of Amortization			$ 46,000
Percentage Of Discount On The Basis Of Recent Trading Price		30
Share Price For Two Or More Consecutive Trading Days		0.01
Patents [Member] | Creative Medical Health Inc [Member] | Scenario One [Member]
Payments Upon Signing Agreement With University For The Initiation Of An Irb Clinical Trial		$ 100,000
Payments Upon Completion Of The Irb Clinical Trial		200,000
Payments In The Event Of Commercialization Of Technology		300,000
Patents [Member] | Creative Medical Health Inc [Member] | Scenario Two [Member]
Payments Upon Filing An Ind With The Fda		100,000
Payments Upon Dosing Of The First Patient In A Phase 1-2 Clinical Trial		200,000
Payments Upon Dosing Of The First Patient In Phase 3 Clinical Trial		$ 400,000
Patents [Member] | Stemspine LLC [Member]
Amortization Expenses			2,500	2,500
Carrying Value Of Patent			$ 52,500
Expiration Period Of Finite-lived Intangible Assets			2027
Expected Amount Of Amortization			$ 10,000
Option [Member]
Initial Payment							$ 100,000
Patent License Agreement [Member]
License Fees			$ 250,000
Number Of Share Issuance Of Common Stock To Jadi Cell			180,180
Amortization Expenses			$ 6,250	6,250
Carrying Value Of Patent			$ 218,750
Expiration Period Of Finite-lived Intangible Assets			2030
Expected Annual Amortization Amount			$ 25,000
Multipotent Amniotic Fetal Stem Cells License Agreement [Member] | Patents [Member]
Amortization Expenses			11,485	11,485
Carrying Value Of Patent			$ 4,084	$ 4,084
Expiration Period Of Finite-lived Intangible Assets			2026
Expected Amount Of Amortization			$ 1,172